Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2014

01-03-2014 | Research Article

High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients

Authors: Jie Chen, Dong Tang, Sen Wang, Qing-Guo Li, Ji-Ran Zhang, Ping Li, Qi Lu, Gang Niu, Jun Gao, Nian-Yuan Ye, Dao-Rong Wang

Published in: Tumor Biology | Issue 3/2014

Login to get access

Abstract

High expressions of galectin-1 and vascular endothelial growth factor (VEGF) are correlated with biological behavior in some cancers. The aim of this study is to evaluate the expressions of galectin-1 and VEGF in gastric cancer and investigate their relationships with clinicopathological factors and prognostic significance. Immunohistochemical analyses for galectin-1 and VEGF expression were performed on 108 cases of gastric cancer. The relationship between the expression and staining intensity of galectin-1 and VEGF, clinicopathological variables, and survival rates was analyzed. Immunohistochemical staining demonstrated that 68 of 108 gastric cancer samples (63.0 %) were positive for galectin-1 and 62 out of 108 gastric cancer samples (57.4 %) were positive for VEGF. Galectin-1 expression was associated with tumor size, differentiation grade, TNM stage, lymph node metastases, and VEGF expression. VEGF expression was related to tumor size, TNM stage, and lymph node metastases. Kaplan–Meier survival analysis showed that high galectin-1 and VEGF expressions exhibited significant correlations with poor prognosis for gastric cancer patients. Multivariate analysis revealed that galectin-1 and VEGF expressions were independent prognostic parameters for the overall survival rate of gastric cancer patients. The results of the present study suggest that galectin-1 expression is positively associated with VEGF expression. Both galectin-1 and VEGF can serve as independent prognostic indicators of poor survival for gastric cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef
3.
Sakaguchi M, Imaizumi Y, Okano H. Expression and function of galectin-1 in adult neural stem cells. Cell Mol Life Sci. 2007;64:1254–8.PubMedCrossRef
4.
Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1999;1473:172–85.PubMedCrossRef
5.
Banh A, Zhang J, Cao H, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011;71:4423–31.PubMedCentralPubMedCrossRef
6.
Kovacs-Solyom F, Blasko A, Fajka-Boja R, et al. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett. 2010;127:108–18.PubMedCrossRef
7.
Thijssen VL, Barkan B, Shoji H, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010;70:6216–24.PubMedCrossRef
8.
Han H, Silverman JF, Santucci TS, Macherey RS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8:72–9.PubMedCrossRef
9.
Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.PubMedCrossRef
10.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.PubMedCrossRef
11.
Mizokami K, Kakeji Y, Oda S, et al. Clinicopathological significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncol. 2006;94:149–54.PubMedCrossRef
12.
Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1 alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946–56.PubMedCrossRef
13.
Saito H, Tsujitani S, Ikeguchi M, et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer. 1998;78:1573–7.PubMedCentralPubMedCrossRef
14.
Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999;86:1455–62.PubMedCrossRef
15.
16.
Watanabe M, Takemasa I, Kaneko N, et al. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep. 2011;25:1217–26.PubMed
17.
Jung EJ, Moon HG, Cho BI, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 2007;120:2331–8.PubMedCrossRef
18.
Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006;16:137R–57R.PubMedCrossRef
19.
Chiariotti L, Salvatore P, Frunzio R, Bruni CB. Galectin genes: regulation of expression. Glycoconj J. 2004;19:441–9.PubMedCrossRef
20.
Zhao XY, Chen TT, Xia L, et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis. 2010;31:1367–75.PubMedCrossRef
21.
Wu MH, Hong TM, Cheng HW, et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res. 2009;7:311–8.PubMedCrossRef
22.
Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006;103:15975–80.PubMedCentralPubMedCrossRef
23.
Barrow H, Rhodes JM, Yu LG. The role of galectins in colorectal cancer progression. Int J Cancer. 2011;129:1–8.PubMedCrossRef
24.
Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer associated immunosuppression and prevents metastatic disease. Cancer Res. 2013;73:1107–17.PubMedCrossRef
25.
Laderach DJ, Gentilini L, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013;73:86–96.PubMedCrossRef
26.
Demydenko D, Berest I. Expression of galectin-1 in malignant tumors. Exp Oncol. 2009;31:74–9.PubMed
27.
Puchades M, Nilsson CL, Emmett MR, et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res. 2007;6:869–75.PubMedCrossRef
28.
Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGFA,-C and -D expression in esophageal malignancies. Onkologie. 2005;28:281–8.PubMedCrossRef
29.
Donnem T, Al-Shibli K, Andersen S, Al-Saad S, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116:4318–25.PubMedCrossRef
30.
Linderholm BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer. 2003;4:340–7.PubMedCrossRef
31.
Kosem M, Tuncer I, Kotan C, et al. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology. 2009;56:1236–40.PubMed
32.
Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther. 2005;4:315–21.PubMedCrossRef
33.
Koopmans SM, Bot FJ, Schouten HC, Janssen J, et al. The involvement of galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. Am J Blood Res. 2012;2:119–27.PubMedCentralPubMed
34.
Fischer I, Schulze S, Kuhn C, Friese K, et al. Inhibition of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. Placenta. 2009;30:1078–82.PubMedCrossRef
35.
Hsieh SH, Ying NW, Wu MH, Chiang WF, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 2008;27:3746–53.PubMedCrossRef
36.
Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer. 2003;97:1849–58.PubMedCrossRef
Metadata
Title
High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients
Authors
Jie Chen
Dong Tang
Sen Wang
Qing-Guo Li
Ji-Ran Zhang
Ping Li
Qi Lu
Gang Niu
Jun Gao
Nian-Yuan Ye
Dao-Rong Wang
Publication date
01-03-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1332-8

Other articles of this Issue 3/2014

Tumor Biology 3/2014 Go to the issue

Research Article

FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data

Research Article

Haplotype analysis of RECQL5 gene and laryngeal cancer

Research Article

Association between glutathione S-transferase T1 null genotype and risk of lung cancer: a meta-analysis of 55 studies

Research Article

High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer

Research Article

Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk

Research Article

Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits